Multivalent Dual Pharmacology Muscarinic Antagonist and β2 Agonist (MABA) Molecules for the Treatment of COPD

Hughes, Adam D.; McNamara, Alexander; Steinfeld, Tod

doi:10.1016/b978-0-12-396493-9.00003-0

Cited by 21 publications

(11 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The development of triple therapies may be aided through the development of muscarinic antagonist-b 2 -agonist molecules, agents that combine muscarinic antagonism and b 2 -agonism in a single molecule [94]. However, issues with dosing flexibility may limit the usefulness of muscarinic antagonist b 2 -agonist molecules [94].…”

Section: The Future Of Copd Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

Addressing unmet needs in the treatment of COPD

Patalano¹,

Banerji²,

D’Andrea³

et al. 2014

Eur Respir Rev

View full text Add to dashboard Cite

The burden of chronic obstructive pulmonary disease (COPD) is considerable, both socially and economically. Central to COPD management is the use of long-acting bronchodilators, which provide patients with optimal bronchodilation and improvements in symptoms. The once-daily, long-acting b 2 -agonist indacaterol, the long-acting muscarinic antagonist glycopyrronium, and the indacaterol/glycopyrronium fixed-dose combination QVA149 have all been shown to significantly improve lung function and patientreported outcomes. The ability to take medication appropriately is important. Easy to use, low resistance devices may help patients take their medication and achieve good drug deposition. There is a need to optimise COPD management by treating the right patients with the right therapy at the right time during the course of their disease. Herein, we present a view on the current COPD management landscape and current unmet needs, and look to the future of COPD treatment and how patient care can be optimised. @ERSpublications There is a need to optimise COPD treatment, with the aim of improving patients' lives

show abstract

Section: The Future Of Copd Treatmentmentioning

confidence: 99%

“…However, issues with dosing flexibility may limit the usefulness of muscarinic antagonist b 2 -agonist molecules [94].…”

Section: The Future Of Copd Treatmentmentioning

confidence: 99%

Addressing unmet needs in the treatment of COPD

Patalano¹,

Banerji²,

D’Andrea³

et al. 2014

Eur Respir Rev

View full text Add to dashboard Cite

show abstract

“…Bi-functional (or dual pharmacophore) muscarinic b 2 -agonist (MABA) agents are a novel approach to ''dual'' bronchodilator therapy by combining muscarinic antagonism and b 2 -agonism in a single molecule [13].…”

mentioning

confidence: 99%

“…The complementary nature of the muscarinic acetylcholine receptor bronchoconstriction and b 2 -adrenoceptor bronchodilation pathways has attracted considerable effort in the discovery of dual pharmacology MABA compounds [13]. The reasons for companies to develop a MABA product are numerous.…”

mentioning

confidence: 99%

“…They include the benefit of delivering a fixed ratio into every region of the lung reducing the complexity of combination inhalers, a single pharmacokinetic profile, a uniform ratio of activities at the cellular level, and a simplified clinical development programme. However, one limitation of MABA molecules is that the ratio of muscarinic antagonism and b 2 -agonism activities cannot be adjusted as needed and this limits dosing flexibility [13].…”

mentioning

confidence: 99%

See 1 more Smart Citation